ClinicalTrials.gg
TerminatedNCT05747794AIPAC-003Updated Jul 30, 2026

Study in Metastatic Breast Cancer Patients Receiving Eftilagimod Alpha or Placebo in Combination With Paclitaxel Chemotherapy

A Phase 2/3 interventional study of eftilagimod alpha and Paclitaxel in Breast Carcinoma, sponsored by Immutep S.A.S.. Terminated at 22 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-30.

Sponsored by Immutep S.A.S. · Phase 2/3, Interventional, and Treatment

Why this study was terminated
Sponsor Decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 905 studies in Breast Neoplasms with a site in Spain — 164 open to participants now, 286 under way, 84 of them phase 3. Breast Neoplasms · Spain.

Enrollment
574th of 805
72 · median 151
Started
2023
with 59 others
Phase 2/3
8 of 905
2 open now
Registered
710th of 905
by date

Among the 905 studies in Breast Neoplasms with a site in Spain, this one is the 574th largest by enrollment of the 805 interventional ones that give a count, is one of 60 that started in 2023, is one of 8 in phase 2/3, and was the 710th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

164 of the 905 studies in Breast Neoplasms with a site in Spain are open now. Recruiting first, the newest first:

159 more — sign in →

All 164 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 905 studies in Breast Neoplasms with a site in Spain, or all of them as a file.
02

Study summary

The goal of this clinical trial is to compare the safety and efficacy of eftilagimod alpha (efti) in combination with paclitaxel standard of care chemotherapy in participants with metastatic breast cancer.

The main questions it aims to answer are:

  • What is the optimal biological dose (OBD) of efti in combination with weekly paclitaxel chemotherapy?
  • Can efti combined with weekly paclitaxel chemotherapy prolong overall survival in participants with metastatic breast cancer if compared to weekly paclitaxel chemotherapy alone?

In the first component of the trial (phase 2, lead-in) researchers will compare two groups (different dose levels of efti in combination with standard chemotherapy) to see if the treatment is safe and well tolerated and evaluate which is the optimal biological dose. In the second component of the trial (phase 3) researchers will assess if the treatment of metastatic breast cancer with the optimal biological dose of efti in combination with paclitaxel is superior compared to chemotherapy alone (placebo-controlled).

The treatment concept of each trial component consists of a chemo-immunotherapy phase followed by an immunotherapy phase. In the first phase participants will be treated with efti plus paclitaxel chemotherapy or placebo plus paclitaxel chemotherapy. After completion of the chemotherapy per standard of care, participants will be treated with the study agent alone.

Read the detailed description

The AIPAC-003 trial consists of an open-label dose optimization lead-in component followed by a double-blinded, randomized, placebo-controlled phase 3 component.

The main objectives of the dose optimization lead-in (phase 2) are to evaluate and compare the safety and tolerability of 2 different dose levels of efti (30 mg and 90 mg) combined with paclitaxel, and to define the optimal biological dose (OBD) of efti in combination with weekly paclitaxel for the phase 3 part of the trial. Recruitment to the dose-optimization lead-in will be considered complete when 29 participants per cohort are randomized and considered evaluable for OBD analysis.

The main objective of the phase 3 is to demonstrate that overall survival (OS) is superior in participants treated with efti combined with weekly paclitaxel compared to weekly paclitaxel plus placebo. Approximately 771 participants will be randomized 2:1 to Arm A (active arm): paclitaxel + efti at OBD and Arm B (control arm): paclitaxel + placebo. The exact patient population will be defined after determination of the OBD.

The duration of the trial will be approximately 24 months for the dose optimization lead-in component and 60 months for the phase 3 component. The phase 3 will start prior to the completion of the phase 2 (once the OBD has been defined).

It is planned to conduct the trial at up to 20 sites in up to 4 countries across North America and Europe for the lead-in and at up to 150 sites in up to 25 countries across North America, Europe, Latin America and the Asian Pacific region for the phase 3.

03

Conditions studied

  • Breast Carcinoma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • HR+ positive (estrogen receptor positive and/or progesterone receptor positive) or hormone receptor negative (HR˗), and -neg breast adenocarcinoma, proven by on the last available tumor tissue
  • Participants with HR+ metastatic breast cancer (MBC) who progressed on or after ≥1 line of endocrine based therapy and are indicated to receive chemotherapy for metastatic disease
  • Participants with HR- MBC (i.e. triple-negative breast cancer [TNBC]) who are indicated to receive paclitaxel chemotherapy without PD 1/ therapy in the setting for metastatic disease
  • performance status 0-1
  • Expected survival longer than three months

Exclusion criteria

Exclusion Criteria:

  • Prior chemotherapy for breast adenocarcinoma
  • Participants with HR+ MBC who have received \<1 line of ET based therapy in the metastatic setting
  • Participants with HR+ MBC who are not primary or secondary resistant to ET-based therapy and would be candidates to ET based therapy as per applicable treatment guidelines
  • TNBC participants who are candidates for /PD-L1 therapy in combination with chemotherapy
  • Disease-free interval of less than twelve months from the last dose of chemotherapy
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
72 participants (actual)

Study arms

  • Experimental
    open label lead-in (phase 2): eftilagimod alpha 30mg + paclitaxel

    eftilagimod alpha 30mg s.c. + 80mg/m\^2 paclitaxel i.v. (same-day administration): The trial consists of a chemo-immunotherapy (chemo-IO) phase followed by an immunotherapy (IO)-phase. The chemo-IO phase consists of a planned 6 cycles of 4 weeks (28 days each) that may be longer or shorter depending on chemo tolerance. The IO-phase is planned to follow the chemo-IO phase. A maximum of 13 cycles (approx. 12 months) of treatment is planned.

    Biological: eftilagimod alpha · Drug: Paclitaxel

  • Experimental
    open label lead-in (phase 2): eftilagimod alpha 90mg + paclitaxel

    eftilagimod alpha 90mg s.c. + 80mg/m\^2 paclitaxel i.v. (same-day administration): The trial consists of a chemo-immunotherapy (chemo-IO) phase followed by an immunotherapy (IO)-phase. The chemo-IO phase consists of a planned 6 cycles of 4 weeks (28 days each) that may be longer or shorter depending on chemo tolerance. The IO-phase is planned to follow the chemo-IO phase. A maximum of 13 cycles (approx. 12 months) of treatment is planned.

    Biological: eftilagimod alpha · Drug: Paclitaxel

  • Experimental
    Phase 3: eftilagimod alpha + paclitaxel

    eftilagimod alpha s.c. (OBD) + 80mg/m\^2 paclitaxel i.v. (same-day administration): The trial consists of a chemo-immunotherapy (chemo-IO) phase followed by an immunotherapy (IO)-phase. The chemo-IO phase consists of a planned 6 cycles of 4 weeks (28 days each) that may be longer or shorter depending on chemo tolerance. The IO-phase is planned to follow the chemo-IO phase. A maximum of 13 cycles (approx. 12 months) of treatment is planned.

    Biological: eftilagimod alpha · Drug: Paclitaxel

  • Placebo comparator
    Phase 3: placebo + paclitaxel

    placebo s.c. + 80mg/m\^2 paclitaxel i.v. (same-day administration): The trial consists of a chemo-immunotherapy (chemo-IO) phase followed by an immunotherapy (IO)-phase. The chemo-IO phase consists of a planned 6 cycles of 4 weeks (28 days each) that may be longer or shorter depending on chemo tolerance. The IO-phase is planned to follow the chemo-IO phase. A maximum of 13 cycles (approx. 12 months) of treatment is planned.

    Drug: Paclitaxel · Other: placebo

Interventions

  • APC activator, MHC II agonist

    Also known as: IMP321, efti, LAG-3Ig, eftilagimod alfa

  • paclitaxel will be given as standard of care (chemotherapy)

  • Otherplacebo

    placebo matching eftilagimod alpha

    Also known as: placebo matching eftilagimod alpha

06

What researchers measure

Primary outcomes

  1. Determination of Overall survival (OS)

    Primary endpoint for Phase 3 portion, secondary endpoint for Phase 2 lead-in portion

    Time frame: Until trial end, death, withdrawal of consent or lost to follow-up, assessed up to 60 months

  2. Determination of the Optimal Biological Dose (OBD)

    Time frame: Up to 15 months

  3. Frequency of adverse events (AEs)

    Time frame: Up to 15 months

  4. Severity of adverse events (AEs)

    Time frame: Up to 15 months

  5. Duration of adverse events (AEs)

    Time frame: Up to 15 months

  6. Occurrence of dose-limiting toxicities (DLTs)

    Time frame: Up to 15 months

Secondary outcomes

  1. Determination of Progression Free Survival (PFS), based on RECIST, v1.1

    Time frame: Until occurrence of progressive disease, or the start of any further next line anticancer treatment, or until the end of the trial for any other reason, assessed up to 60 months

  2. Evaluation of Objective Response Rate (ORR) based on RECIST v1.1

    Time frame: Until occurrence of progressive disease, or the start of any further next line anticancer treatment, or until the end of the trial for any other reason, assessed up to 60 months

07

Study locations

22 sites
  • The Oncology Institute
    Whittier, California 90602, United States
  • The George Washington University Cancer Center
    Washington D.C., District of Columbia 20037, United States
  • Carolina Blood and Cancer Care Associates
    Rock Hill, South Carolina 29723, United States
  • Oncology Consultants
    Houston, Texas 77024, United States
  • The University of Texas MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • AZ Sint-Jan Brugge Oostende av
    Bruges, Belgium
  • Cliniques Universitaires Saint-Luc
    Brussels, 1200, Belgium
  • Grand Hopital de Charleroi - Hopital Notre Dame
    Charleroi, 6000, Belgium
  • Universitair Ziekenhuizen Antwerpen
    Edegem, 2650, Belgium
  • Centre Hospitalier de l'Ardenne
    Libramont, 6800, Belgium
  • Clinique Saint-Pierre- Ottignies
    Ottignies-Louvain-la-Neuve, Belgium
  • ARENSIA Exploratory Medicine LLC
    Tbilisi, Georgia
  • ARENSIA Exploratory Medicine Phase I Unit
    Chisinau, 2025, Moldova
  • Institut Català d'Oncologia
    Badalona, 08916, Spain
  • VHIO - Hospital Vall d'Hebron
    Barcelona, 08035, Spain
  • Hospital Clinic de Barcelona
    Barcelona, 08036, Spain
  • Parc Taulí Hospital Universitari
    Barcelona, 08208, Spain
  • Hospital Universitario Reina Sofia
    Córdoba, 14004, Spain
  • Hospital Universitario de Jaén
    Jaén, 23007, Spain
  • Unidad Ensayos Clínicos Oncología Fundació IRB Lleida
    Lleida, 25196, Spain
  • START Madrid - FJD, Hospital Fundación Jiménez Diaz
    Madrid, 28040, Spain
  • Hospital Universitario La Paz
    Madrid, 28046, Spain
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2023 to primary completion in Apr 2026, 35 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 2, 2023
First posted
Feb 28, 2023
StartActual
May 22, 2023
Primary completionActual
Apr 30, 2026
CompletionActual
Jun 30, 2026
Last update
Jul 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05747794
Lead sponsor
Immutep S.A.S.
Responsible party
Sponsor
First posted
Feb 28, 2023
Start date
May 22, 2023
Primary completion
Apr 30, 2026
Completion
Jun 30, 2026
Last update
Jul 30, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Etilagimod alpha

Start the discussion